ArticlePediatric nephrology (Berlin, Germany)2026
Mycophenolate mofetil versus tacrolimus for maintenance of remission in children with frequently relapsing and steroid-dependent nephrotic syndrome: a pilot randomized controlled trial.
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFrequently relapsing nephrotic syndrome (FRNS) and steroid-dependent nephrotic syndrome (SDNS) require steroid-sparing agents to maintain remission and reduce steroid-related toxicity. Comparative evidence between mycophenolate mofetil (MMF) and tacrolimus (TAC) remains limited. The objective of this study was to compare the efficacy and safety of MMF and TAC for maintenance of remission in children with FRNS/SDNS.
methodsThis prospective, open-label, pilot randomized controlled trial was conducted at a tertiary care centre in India between October 2023 and March 2025. Children aged 2-18 years with FRNS or SDNS receiving only prior corticosteroids were randomized (1:1) to MMF (1200 mg/m
resultsForty patients were enrolled (20 in each group). Relapse-free survival at 6 months was comparable between groups, with no significant difference in time to first relapse. Sustained remission and overall relapse rates over 12 months were also similar. Kidney function was significantly better preserved in the MMF group, whereas TAC was associated with higher serum creatinine and lower eGFR. Blood pressure and body mass index were higher in the TAC group, while growth velocity was greater in the MMF group. Adverse events were mostly mild and comparable.
conclusionsMMF and TAC showed comparable efficacy in maintaining remission in children with FRNS/SDNS. However, TAC was associated with less favourable kidney, cardiovascular, and growth profiles. MMF may represent a safer alternative for long-term therapy, although larger multicentre trials are needed.
Indexed as
Identifiers
42704437What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.